Evidence map›Paper›PMID 28064445›Full record

ArticleCancer science2017

Panel of autoantibodies against multiple tumor-associated antigens for detecting gastric cancer.

Isamu Hoshino, Matsuo Nagata, Nobuhiro Takiguchi, Yoshihiro Nabeya, Atsushi Ikeda, Sana Yokoi, Akiko Kuwajima, Masatoshi Tagawa, Kazuyuki Matsushita, Yajima Satoshi and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer science, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 1 pooled it
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 1 synthesis or guideline pooled it, 52 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Observational
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Isamu HoshinoDivision of Gastroenterological Surgery, Chiba Cancer Center, Chiba, Japan.
Matsuo NagataDivision of Gastroenterological Surgery, Chiba Cancer Center, Chiba, Japan.
Nobuhiro TakiguchiDivision of Gastroenterological Surgery, Chiba Cancer Center, Chiba, Japan.
Yoshihiro NabeyaDivision of Gastroenterological Surgery, Chiba Cancer Center, Chiba, Japan.
Atsushi IkedaDivision of Gastroenterological Surgery, Chiba Cancer Center, Chiba, Japan.
Sana YokoiDivision of Chemotherapy and Cancer Diagnosis, Chiba Cancer Center, Chiba, Japan.
Akiko KuwajimaMedical & Biological Laboratories Co., Ltd, Nagoya, Japan.
Masatoshi TagawaDivision of Pathology and Cell Therapy, Chiba Cancer Center, Chiba, Japan.
Kazuyuki MatsushitaDivision of Clinical Genetics and Proteomics, Department of Laboratory Medicine, Chiba University Hospital, Chiba, Japan.
Yajima SatoshiDepartment of Surgery, School of Medicine, Toho University, Tokyo, Japan.
Shimada HideakiDepartment of Surgery, School of Medicine, Toho University, Tokyo, Japan.
Chiba Cancer Center · JPToho University · JPChiba University Hospital · JPMedical & Biological Laboratories (Japan) · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gastric cancer is the second leading cause of cancer death in the world, and effective diagnosis is extremely important for good outcome. We assessed the diagnostic potential of an autoantibody panel that may provide a novel tool for the early detection of gastric cancer. We analyzed data from patients with gastric cancer and normal controls in test and validation cohorts. Autoantibody levels were measured against a panel of six tumor-associated antigens (TAAs) by ELISA: p53, heat shock protein 70, HCC-22-5, peroxiredoxin VI, KM-HN-1, and p90 TAA. We assessed serum autoantibodies in 100 participants in the test cohort. The validation cohort comprised 248 participants. Autoantibodies to at least one of the six antigens showed a sensitivity/specificity of 49.0% (95% confidence interval [CI], 39.2-58.8%)/92.4% (95% CI, 87.2-97.6%), and 52.0% (95% CI, 42.2-61.8%)/90.5% (95% CI, 84.8-96.3%) in the test and validation cohorts, respectively. In the validation cohort, no significant differences were seen when patients were subdivided based on age, sex, depth of tumor invasion, lymph node metastasis, distant metastasis, peritoneal dissemination, or TNM stage. Patients who were positive for more than two antibodies in the panel tended to have a worse prognosis than those who were positive for one or no antibody. Measurement of autoantibody response to multiple TAAs in an optimized panel assay to discriminate patients with early stage gastric cancer from normal controls may aid in the early detection of gastric cancer.

Indexed as

AdultAgedAged, 80 and overAntigens, NeoplasmAutoantibodiesAutoantigensBiomarkers, TumorEnzyme-Linked Immunosorbent AssayFemaleHSP70 Heat-Shock ProteinsHumansIntracellular Signaling Peptides and ProteinsMaleMembrane ProteinsMiddle AgedNeoplasm ProteinsAntigens, NeoplasmAutoantibodiesAutoantigensBiomarkers, TumorCCDC110 protein, humanCIP2A protein, humanHCC-22-5 antigen, humanHSP70 Heat-Shock ProteinsIntracellular Signaling Peptides and ProteinsMembrane ProteinsNeoplasm ProteinsNuclear ProteinsPeroxiredoxin VITP53 protein, humanTumor Suppressor Protein p53Autoantibodygastric cancerp53panelprognosis

Identifiers

PMID28064445
PMCPMC5378227
OpenAlexW2567754274

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.